HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of the long term aspirin administration on the progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse.

AbstractUNLABELLED:
We have investigated the effects of differential aspirin doses on atherogenesis. Aspirin was given to homozygous, apoE(-/-) and LDLR(-/-) double deficient mice for 12 weeks. The development of arteriosclerosis was determined morphologically by image analysis and endothelial cell function was assessed by measurement of peripheral nitric oxide (NO).
METHODS:
ApoE(-/-) LDLR(-/-)double knockout mice were bred and maintained with a high fat diet containing aspirin (4 and 40 mg/kg B.W. /day) for twelve weeks. The development of arteriosclerosis was monitored by estimating the total area of atherosclerotic lesions in the entire aorta. Acetylcholine-induced NO release was measured in vivo using electrochemical sensors. The expression of eNOS on the endothelial surface was determined by immuno-staining. Plasma prostaglandin F1alpha (PGF(1 alpha)), serum thromboxian B(2) (TXB(2)) and total cholesterol were measured using enzymatic assay. Bleeding time was measured by tail cut method.
RESULTS:
Arteriosclerosis in the 4 mg/kg/day aspirin group was decreased significantly compared with the placebo group, but not in the 40 mg/kg/day aspirin group. Acetylcholine-induced NO release was significantly depressed in the 40 mg/kg/day aspirin group. Immunochemical analysis with anti-eNOS antibody supported these findings. In the 4 mg/kg/day aspirin group, the severe suppression of PGI(2) production was not confirmed in spite of decreasing TXB(2) production, but not in the 40 mg/kg/day aspirin group.
CONCLUSION:
Our results suggest that endothelial dysfunction with low dose aspirin improved, reduced progression of atherosclerosis in apoE(-/-) and LDLR(-/-) double deficient mice and provides a pathophysiological basis for the beneficial effects of aspirin in atherosclerosis, and low doses appeared to be more efficient than high doses.
AuthorsY Yamamoto, T Yamashita, F Kitagawa, K Sakamoto, J C Giddings, J Yamamoto
JournalThrombosis research (Thromb Res) Vol. 125 Issue 3 Pg. 246-52 (Mar 2010) ISSN: 1879-2472 [Electronic] United States
PMID20005558 (Publication Type: Journal Article)
Copyright(c) 2009 Elsevier Ltd. All rights reserved.
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Apolipoproteins E
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Acetylcholine
  • Aspirin
Topics
  • Acetylcholine (pharmacology)
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal (pharmacology)
  • Aorta (pathology)
  • Apolipoproteins E (deficiency)
  • Aspirin (pharmacology)
  • Atherosclerosis (pathology)
  • Diet, Atherogenic
  • Dose-Response Relationship, Drug
  • Endothelial Cells (metabolism)
  • Endothelium, Vascular (metabolism)
  • Homozygote
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Knockout
  • Nitric Oxide (analysis, metabolism)
  • Nitric Oxide Synthase Type III (analysis, metabolism)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: